NeurosciencebioRxivPreprint
Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathy.
Jonathan P. Hulse, Nicole M. Maphis, Julianne Peabody…·Kiran Bhaskar
This study compares two VLP-based vaccines targeting different pTau epitopes, finding that the PHF1 vaccine reduces tau pathology and restores cognition better than the AT8 vaccine in a mouse model.
1 citation